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ABSTRACT
The systemic lupus erythematosus (SLE) is an autoimmune disease affecting predominantly females of reproductive age group. 
Pregnancy is advised only after a period of disease quiescence for at least six months. Azathioprine (AZA) and prednisolone are 
the immunosuppressants commonly used during pregnancy in lupus nephritis. Azathioprine causing cholestatic jaundice has been 
reported only a few times but none in a patient with lupus nephritis, pregnant or otherwise to the best of our knowledge. We present 
an interesting case of a young pregnant patient of lupus nephritis (LN) developing cholestatic jaundice in the third trimester, causing 
diagnostic dilemma between drug-induced jaundice and Intrahepatic cholestasis of pregnancy which resolved after withholding 
azathioprine. We should be aware of this uncommon adverse effect of this very commonly used drug in SLE patients.
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Azathioprine is a derivative of thioguanine, a purine-mimic antimetabolite. It has been extensively used in organ transplant and various autoimmune diseases. Use 
of azathioprine in pregnancy complicated by systemic lupus 
erythematosus (SLE) has limited data restricted to one cohort 
of 31 pregnancies. The authors reported favorable outcomes 
and, consequently, recommended azathioprine for the treatment 
of SLE/Lupus nephritis (LN) in pregnancy [1]. It along with 
prednisolone is the immunosuppressant of choice in pregnancy.
CASE REPORT
A 25-years-old female, an old case of lupus nephritis Class III 
+ V with initial presentation as a nephrotic syndrome (anasarca, 
hypoproteinemia) which was diagnosed four years ago received 
Mycophenolate mofetil (MMF) and prednisolone as induction 
therapy achieving remission and was on same drugs in 
continuation phase with no relapse. As she expressed the desire 
for pregnancy, she was switched to azathioprine (AZA) from 
MMF six months prior to conception and she had no disease 
activity when she conceived one year ago. 
Clinically, she had no cutaneous manifestations of SLE, pallor, 
pedal edema and her other general and systemic examination was 
unremarkable. Her investigations in the first month of pregnancy 
were haemoglobin-10.9 gm/dl, serum urea/creatinine-18/0.6 
mg/dl, serum protein/ albumin-7.0/3.9 gm/dl, Urine routine and 
microscopic examination (RE/ME) showed no RBCs/ cast, 24 
hour urinary protein – 310 mg, complement factor 3(C3) – 154 
mg/dl (Normal – 90- 180), Complement factor 4(C4) – 34 mg/
dl (Normal- 10-40), double-stranded DNA (dsDNA) – 10.8 IU/L 
(Normal <30), beta 2 glycoprotein and anticardiolipin antibody 
were within normal limits. 
She was continued on AZA 100 mg/day, Prednisolone10 mg/
day, Hydroxychloroquine 400 mg/day and Ecosprin 75 mg/day. 
During follow-up, she had poor weight gain and during anomaly 
scan on Ultrasound (USG), intrauterine growth retardation 
Table 1: Investigations Chart
Day
32 wks (D-Day 
of admission)
D+5 
(Delivery)
D+7 (Aza 
withheld)
D+14 D+21 D+28
Hb 9.2 9.4
Bil (D/I) 5.6 (3.2/2.4)
11.8 
(8.0/2.8)
18 
(10.4/7.6)
10.2 4.6 1.5
AST 29 57 123 68 45 34
ALT 29 67 148 76 63 35
Alk PO4 178 210
Serum 
Bile acids
40
USG Abd
Normal hepato-
biliary system
C3 127
C4 30.3
dsDNA 10.3
Peripheral 
smear
No evidence of 
hemolysis
24 hrs 
urinary 
protein
510 mg/TV
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(IUGR) was detected at 18 weeks with no other anomalies and 
pregnancy was continued with regular monitoring. She had 
no features of increased disease activity either clinically or 
by laboratory parameters during follow up. At 32-weeks, she 
developed insidious onset jaundice with itching and clay coloured 
stools. Clinically, she had icterus with no hepatomegaly. Her 
initial bilirubin was 5.6 mg/dl with slightly raised transaminases; 
(laboratory parameters are given in Table 1) giving a provisional 
diagnosis of intrahepatic cholestasis of pregnancy (IHCP).
Ursodeoxycholic acid (UDCA) was started with mild relief 
of itching. She had premature rupture of membranes on the 
5th day following admission and delivered a low birth weight 
baby per vagina. As she had worsening jaundice even after 
delivery, her azathioprine was withheld with rapid resolution 
of hyperbilirubinemia. Her bilirubin normalized by three weeks 
after withholding AZA confirming the diagnosis of Azathioprine 
induced cholestatic jaundice. On follow-up, she has no disease 
activity with normal lab parameters (Bilirubin -0.6 mg/dl) or 
other complications and the child is doing well.
DISCUSSION
SLE primarily affects women during their reproductive years, a 
period of six months of quiescence is recommended as the activity 
at the time of conception is associated with poor outcomes [2]. 
Patients with SLE have higher complication rates in both mother 
and child like preterm labor, preeclampsia, eclampsia, infections, 
thrombosis, neonatal death and fetal growth restriction as in 
our patient [3]. The immunosuppressant drugs considered for 
use in pregnant lupus patients are corticosteroids, azathioprine, 
tacrolimus and cyclosporine [4].
AZA is considered the safest immunosuppressant in pregnancy 
[1]. AZA has been associated with four forms of hepatotoxicity, 
including mild, transient and asymptomatic rises in serum 
Table 2: Previously reported cases of azathioprine induced cholestatic Jaundice 
Year Case report /Series Journal No of patients Indication
Onset of 
Jaundice after 
initiation
Diagnosis
1980 CR Davis et alPostgraduate medical journal 1 Chronic active hepatitis 2 weeks Clinical
1984 CR Depinho et alGasstroenterology 1 SLE 3 WKS Clinical
1990 CR Perini et alJ Heart Transplant 1 Post cardiac transplant Clinical
1991 CS Sterneck  et al, Hepatology 2 Liver transplant 2 & 9 wks Clinical
2005 CR
Eisenbach et al 
Immunopharmaco 
Immunotoxic
1 DLE 3 Liver biopsy
2010 CR Salem et alPharmacy world science 1 Pemphigus foliaceous 3 weeks
Enzyme 
activity
2011 CR Viju et alIJ pharmacology 1 Post Keratoplasty 2 weeks Liver Biopsy
2014 CR Chertoff et alBMJ 1 Myas Gravis 12 months Enzyme
2017 CS Bjornsson et al (5)J Clin gastro 12 IBD, autimmune,pulmonary
41 days 
(Median)
Liver biopsy + 
Clinical
Table 3: Naranjo Adverse Drug Reaction Probability Scale
Question Yes No
Don’t 
Know
Score
Are there previous conclusive 
reports on this reaction? +1 0 0 +1
Did the adverse event appear 
after the suspected drug was 
administered?
+2 -1 0 +1
Did the adverse reaction improve 
when the drug was discontinued 
or a specific antagonist was 
administered?
+1 0 0 +1
Did the adverse event reappear when 
the drug was re-administered? +2 -1 0 0
Are there alternative causes (other 
than the drug) that could on their 
own have caused the reaction?
-1 +2 0 +2
Did the reaction reappear when a 
placebo was given? -1 +1 0 0
Was the drug detected in blood 
(or other fluids) in concentrations 
known to be toxic?
+1 0 0 0
Was the reaction more severe when 
the dose was increased or less severe 
when the dose was decreased?
+1 0 0 0
Did the patient have a similar 
reaction to the same or similar drugs 
in any previous exposure?
+1 0 0 0
Was the adverse event confirmed by 
any objective evidence? +1 0 0 0
TOTAL SCORE 5
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aminotransferase levels, an acute cholestatic injury, and chronic 
hepatic injury markedby veno-occlusive disease or nodular 
regenerative hyperplasia that typically occursafter long term use [5]. 
It has been mentioned as a cause of cholestatic jaundice in pregnancy 
seen in post-transplant patients [6]. No reports are suggesting an 
increased risk of IHCP in lupus patients [7] which was a strong 
possibility in our case but bilirubin rarely rises above 6 mg/dl in 
IHCP [8]. AZA causing cholestatic jaundice is a rarity which has 
been reported in few case reports and series so far (Table 2).
The mean time for onset of jaundice varies from as less as 
few days and rarely exceeded six months in the largest case 
series [5], it was 8 months in our patient. Our patient had 
shown improvement immediately after stopping AZA with a 
resolution of jaundice and normalization of liver functions tests 
(LFTs) suggesting the role of AZA with high probability as in 
Naranjo Nomogram (Table 3). The other methods that can be 
used are measuring methylmercarcaptopurine levels [9] or the 
demonstration of the cholestatic pattern on liver biopsy. We didn’t 
intend on doing a liver biopsy as there was a rapid resolution of 
symptoms, and methylmercaptopurine levels were not available 
at our center. There have been studies on azathioprine in pregnant 
lupus patients or but none mentions this complication [1, 10, 11]. 
CONCLUSION
To conclude, we want to highlight this uncommon complication 
of a very commonly used drug in lupus patients. One should be 
more vigilant of jaundice in a patient using azathioprine even 
after a long duration of use.
REFERENCES
1. Clowse MEB. Lupus activity in pregnancy. Rheum Dis Clin North Am. 
2007;33:237-52. 
2. Kwok LW, Tam LS, Zhu T, Leung YY, Li E. Predictors of maternal and foetal 
outcomes in pregnancies of patients with systemic lupus erythematosus. 
Lupus. 2011;20:829.
3. Yasmeen S, Wilkins EE, Field NT, Sheikh RA, Gilbert WM. Pregnancy 
outcomes in women withsystemic lupus erythematosus. J Matern Fetal Med. 
2001;10:91-6
4. Stanhope TJ, White WM, Moder KG, Smyth A, Garovic VD. Obstetric 
nephrology: lupus and lupus nephritis in pregnancy. Clin J Am Soc Nephrol. 
2012;7:2089-99.
5. Bjornson ES, Gu J, Kleiner DE, Chalasani N, Hayashi PH, Hoofnagle JH 
et al. Azathioprine and 6-Mercaptopurine Induced Liver Injury: Clinical 
Features and Outcomes. J Clin Gastroenterol. 2017;51:63.
6. Cunningham GF, Leveno KJ, Bloom S, et al. Williams Obstetrics. 24th ed. 
New York, NY: McGraw-Hill; 2013:1084-87   
7. Ghosh S, Chaudhuri S. Intra-hepatic cholestasis of pregnancy: a 
comprehensive review. Indian J Dermatol. 2013;58:327.
8. Ozkan S, Ceylan Y, Ozkan OV, Yildirim S. Review of a challenging clinical issue: 
Intrahepatic cholestasis of pregnancy. World J Gastroenterol. 2015;21:7134.
9. Kontorinis N, Agarwal K, Gondolesi G, Fiel MI, O’rourke M, Schiano TD. 
Diagnosis of 6 mercaptopurine hepatotoxicity post liver transplantation 
utilizing metabolite assays. Am J Transplant.2004;4:1539-42.
10. Sharon E, Jones J, Diamond H, Kaplan D. Pregnancy and azathioprine in 
systemic lupus erythematosus. Am J Obstet Gynecol. 1974;118:25-8.
11. Abu-Shakra M, Shoenfeld Y. Azathioprine therapy for patients with systemic 
lupus erythematosus. Lupus. 2001;10:152-3.
Funding: None; Conflict of Interest: None Stated.
How to cite this article: Chauhan P, Singh S, Singh J. Azathioprine causing 
cholestatic jaundice in a lupus nephritis patient: a case report and review of 
literature. Indian J Case Reports. 2019;5(4):351-353. 
Doi: 10.32677/IJCR.2019.v05.i04.019
